NCT02723006: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma |
|
|
| Terminated | 1 | 22 | US | TAK-580, MLN2480, TAK-202, MLN1202, plozalizumab, vedolizumab, Entyvio, nivolumab, Opdivo, ipilimumab, Yervoy | Millennium Pharmaceuticals, Inc. | Melanoma | 05/18 | 05/18 | | |